Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 3/20 | 1.00 |
| ▸ | CXCL12 | P48061 | 7/20 | 0.86 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.76 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.74 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.72 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.72 |
| ▸ | MAOA | P21397 | 1/20 | 0.67 |
| ▸ | MAOB | P27338 | 1/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.67 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.67 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.67 |
| ▸ | RELA | Q04206 | 1/20 | 0.67 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5088005 | 1.00 | AR (1.00) | ARCXCL12CHRNA7CXCR4PTGS1 | |
| SCHEMBL5432809 | 0.94 | AR (1.00) | ARCXCL12CHRNA7CXCR4MAOA | |
| SCHEMBL5432805 | 0.94 | AR (1.00) | ARCXCL12CHRNA7CXCR4MAOA | |
| SCHEMBL25199657 | 0.90 | CXCL12 (1.00) | ARCXCL12CHRNA7CXCR4PTGS1 | |
| SCHEMBL5426813 | 0.88 | AR (0.79) | ARCXCL12CHRNA7MAOAMAOB | |
| SCHEMBL5426819 | 0.88 | AR (0.79) | ARCXCL12CHRNA7MAOAMAOB | |
| SCHEMBL5137911 | 0.86 | CHRNA7 (1.00) | ARCXCL12CHRNA7PTGS1PTGS2 | |
| SCHEMBL5137913 | 0.86 | CHRNA7 (1.00) | ARCXCL12CHRNA7PTGS1PTGS2 | |
| SCHEMBL14692635 | 0.85 | MAOB (0.83) | ARMAOAMAOBMEN1KMT2A | |
| SCHEMBL25194287 | 0.85 | CXCL12 (1.00) | ARCXCL12CXCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190008797-A1 | ESTROGEN RECEPTOR ALPHA COLIGANDS, AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2019-01-10 | — | — | US | disclosed |
| WO-2007115181-A9 | COMPOUNDS EXHIBITING EFFLUX INHIBITOR ACTIVITY AND COMPOSITIONS AND USES THEREOF | EASTMAN CHEM CO (US) | 2008-04-03 | — | — | WO | disclosed |
| US-20070254859-A1 | Compounds exhibiting efflux inhibitor activity and composition and uses thereof | EASTMAN CHEMICAL COMPANY | 2007-11-01 | — | — | US | disclosed |
| WO-2007115181-A2 | COMPOUNDS EXHIBITING EFFLUX INHIBITOR ACTIVITY AND COMPOSITIONS AND USES THEREOF | EASTMAN CHEMICAL COMPANY (US) | 2007-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254859-A1 | Compounds exhibiting efflux inhibitor activity and composition and uses thereof | ABCC4, NCOA4, NR4A3 | AR 152/4885CXCL12 2220/4885CHRNA7 684/4885 |
| US-20190008797-A1 | ESTROGEN RECEPTOR ALPHA COLIGANDS, AND METHODS OF USE THEREOF | ESRRG, GPER1, ESR2 | AR 143/4885CXCL12 2622/4885CHRNA7 133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.